Canaccord Genuity Agrees UK Wealth Sale and a Conditional, Currency-Linked Take-Private

The twin Sunday deals would hand shareholders cash for both halves of the company — if regulators, courts and a 45-day search for a better bid let them close.

Sources

Sources & evidence

What “Source checked” means

Canaccord Genuity agreed on Sunday to sell its UK wealth business and be taken private by its own chief executive, in two linked deals that would end its public listing.

Two deals, announced together

Canaccord Genuity Group Inc. (TSX: CF) announced both transactions on Sunday, November 15, 2026.

The first is a definitive agreement to sell the UK & Crown Dependencies wealth business, known as CGWM UK. The second is a plan of arrangement — a court-approved takeover structure — under which a company wholly owned by Chairman and Chief Executive Dan Daviau would buy the rest.

The two deals are linked in one direction only. The take-private cannot complete unless the UK sale completes first. The UK sale is not contingent on the take-private and is intended to proceed either way.

What the UK sale pays

A newly formed entity jointly owned by Centerbridge Partners and Mubadala Investment Company will acquire the entire issued share capital of the Jersey holding company for CGWM UK, in an all-cash transaction.

The transaction values CGWM UK at an enterprise value of approximately £1.17 billion. Canaccord holds an approximate 66.9% equity equivalent interest in the business, on an as-converted basis, subject to liquidation preferences.

The company expects to receive proceeds of approximately £564 million. That is after adjustments for debt and working capital, transaction costs and closing timing.

After closing, CGWM UK will be jointly owned by Centerbridge and Mubadala, with management and employees retaining a meaningful ownership interest. It will keep operating under the Canaccord Wealth brand under a two-year brand license agreement.

Canaccord Wealth chief executive David Esfandi said its assets under management and revenues had almost tripled over the past decade. Canaccord's UK capital markets business is not part of the sale and remains integral to the global platform.

A headline price that moves with the pound

Shareholders are offered aggregate cash consideration built from two parts. The first is a fixed $7.45 per common share, attributable to the remaining business after the UK sale.

The second is £4.15 per share, the amount attributable to each share from the anticipated UK sale proceeds. It stays in pounds until closing, when it converts into Canadian dollars at the rate then in effect.

At the November 13, 2026 exchange rate, that £4.15 was worth approximately $7.82. Adding the fixed $7.45 gives approximately $15.27 per share — a calculation at that date's rate, not a fixed price.

No hedging arrangement will be put in place. If sterling weakens before closing, the Canadian-dollar total falls with it; if sterling strengthens, the total rises.

Series C preferred holders face no such swing. They would receive $25.30 per share in cash, plus accrued and unpaid dividends.

At the November 13 rate, the $15.27 total represents a 26.7% premium to the $12.05 close on February 13, 2026. It is also a 7.8% premium to the 30-day volume-weighted average price for the period ended November 13, 2026.

The safeguards around an insider bid

Because Daviau wholly owns the buyer, the transaction is a business combination under MI 61-101, Canada's minority-protection rule for insider transactions. That rule requires an independent formal valuation and a separate majority-of-the-minority vote.

A special committee of independent directors, chaired by Lead Independent Director Michael Auerbach, negotiated the terms. The committee unanimously recommended the deal, and the board unanimously approved it, with Daviau abstaining.

INFOR Financial's formal valuation put the fair market value of the common shares at $14.60 to $15.67 per share. The $15.27 headline total sits inside that range.

The transaction is not subject to a financing condition. It will be funded through fully committed debt and preferred equity financing, plus the company's UK sale proceeds.

Holders of approximately 35% of the outstanding common shares have indicated support, counting shares issuable on conversion of convertible debentures. Daviau himself holds approximately 6.6 million shares, about 6.3% on the same conversion basis.

The agreement carries a 45-day go-shop — a window to actively solicit a better offer — ending December 30, 2026. Afterward, non-solicitation terms apply, with a fiduciary out for superior proposals and a matching right for the buyer.

A termination fee of $41.6 million is payable in certain circumstances, including a termination to accept a superior proposal.

The committee's case rested on what would be left behind. After the sale, the company would be smaller and less diversified, more weighted to cyclical capital markets earnings, and its shares have persistently traded at a discount to peers.

Results that landed the same day

Canaccord also reported second-quarter fiscal 2027 results on Sunday, for the quarter ended September 30, 2026.

On an adjusted basis excluding significant items, revenue was $603.7 million, up 13.8% year over year. Adjusted diluted earnings per common share were $0.43, up 59.3%, and adjusted net income before taxes was $84.0 million.

The IFRS figures tell a different story, and the two bases must not be mixed. IFRS revenue was $604.0 million, up 12.7%, but the IFRS result was a diluted loss of $0.25 per share.

The business being sold earned $131.6 million of revenue in the quarter, up 1.8%. Its client assets reached $81.7 billion (£43.3 billion), up 10.4%, and its normalized EBITDA was £23.7 million, up 5.5%.

Global wealth revenue was $304.7 million and total client assets hit a record $162.3 billion. Capital markets revenue was $286.8 million, up 13.5%.

The company cancelled the earnings call set for November 17, 2026, in light of the transactions. It will also provide no further guidance for fiscal 2027, though it intends to keep paying quarterly dividends until the take-private completes.

What remains unknown

Whether a better offer appears during the go-shop. No competing proposal exists today, the window closes on December 30, 2026, and any superior proposal would still face the buyer's matching right.

Whether shareholders and the court approve. The arrangement needs two-thirds of common votes, a majority of the minority under MI 61-101, two-thirds of the Series C class voting separately, and approval from the Supreme Court of British Columbia. The meeting is expected in the first quarter of calendar 2027.

Whether regulators clear the UK sale, including the UK Financial Conduct Authority and the authorities in Jersey, Guernsey and the Isle of Man. Both transactions are expected to close in the first half of calendar 2027.

What the final price actually is. Until the pound amount converts at closing, $15.27 remains an estimate at one day's exchange rate. Monday's TSX open will give the first market verdict on both deals.

Sources & evidence

Source checked3 sources · 18 figures

Figure receipts

Every figure in this article, with the source it came from.

  • 7.45 Fixed consideration per common share

    CAD · CAD · As of Nov. 15, 2026

  • 4.15 GBP amount per common share

    GBP · GBP · As of Nov. 15, 2026

  • 7.82 GBP amount per share in CAD at Nov. 13, 2026 rate

    CAD · CAD · As of Nov. 15, 2026

  • 15.27 Total consideration per common share at Nov. 13, 2026 rate

    CAD · CAD · As of Nov. 15, 2026

  • 25.30 Series C preferred consideration per share

    CAD · CAD · As of Nov. 15, 2026

  • 14.60 INFOR formal valuation range, low end

    CAD · CAD · As of Nov. 15, 2026

  • 15.67 INFOR formal valuation range, high end

    CAD · CAD · As of Nov. 15, 2026

  • 35 Indicated common shareholder support

    % · As of Nov. 15, 2026

  • 41.6 Termination fee

    CAD · CAD million · As of Nov. 15, 2026

  • 603.7 Q2 fiscal 2027 adjusted revenue

    CAD · CAD million · As of Nov. 15, 2026

  • 0.43 Q2 fiscal 2027 adjusted diluted earnings per share

    CAD · CAD · As of Nov. 15, 2026

  • 0.25 Q2 fiscal 2027 IFRS diluted loss per share

    CAD · CAD · As of Nov. 15, 2026

  • 131.6 UK & Crown Dependencies wealth Q2 revenue

    CAD · CAD million · As of Nov. 15, 2026

  • 81.7 UK & Crown Dependencies client assets

    CAD · CAD billion · As of Nov. 15, 2026

  • 23.7 UK & Crown Dependencies normalized EBITDA, Q2

    GBP · GBP million · As of Nov. 15, 2026

  • 1.17 CGWM UK enterprise value

    GBP · GBP billion · As of Nov. 15, 2026

  • 564 Expected sale proceeds to the company

    GBP · GBP million · As of Nov. 15, 2026

  • 66.9 Company equity equivalent interest in CGWM UK

    % · As of Nov. 15, 2026

All dates 2026.

TickerGrove house illustration for banking coverage: a bank facade with columns and an arched door

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Markets · All stories